This service is provided by ARS in accordance with the Decision of the Council of the Eurasian Economic Commission of November 3, 2016 N 88 «On the Adoption of the Requirements for the Medication Guide and Summary of Product Characteristics of medicinal products for human use.»
User testing or justification of its absence is mandatory in accordance with the Decision of the Council of the Eurasian Economic Commission of November 3, 2016 N 78 «On the Rules for the registration and examination of medicines for medical use» (Appendix 16).
User testing demonstrates how the patient leaflet works in practice, identifies barriers that reduce the ability of people to understand and use the information presented, and also open up problem areas that require adjustment.
The patient leaflet user testing includes the following steps:
User testing protocol development
Selection and training of the interviewer
Recruitment of the target participants
Review of pilot test results and making changes to the test protocol of the patient leaflet
Conducting the main testing phase
Processing of the user testing results
Drawing up a report on the results of user testing, including but not limited to:
Brief description of the dosage form
Brief description of the conducted testing
Used questionary and feedback forms
Original and revised Patient leaflet
Brief description and discussion of test results
Each of these steps includes a set of necessary aspects and regulatory requirements. A user testing report must be attached to the registration dossier for examination.
OUR COMPETITIVE ADVANTAGES:
Years of experience in this field
Respondents in the database
© ARS PHARMRUSSIA: CLINICAL & REGULATORY EXPERT CRO, 2009-2024
All rights reserved.